
    
      An open-label, randomised, four period crossover study to investigate the relative
      pharmacokinetic profiles of tablets from three batches of firategrast with different surface
      areas and two different tablet formulations containing the same batch of firategrast, given
      as single 900mg doses to male and female subjects with a diagnosis of Multiple Sclerosis
    
  